Aclaris Therapeutics (ACRS) vs Geron (GERN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Geron (GERN) over the past year, gaining 37.1% versus a loss of 22.3%. Over five years, GERN leads with a -40.8% price change compared with -72.7% for ACRS. Geron is the larger company by market cap ($560.9 million vs $545.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | GERN |
|---|---|---|
| Share price | $3.44 | $0.8707 |
| Market cap | $545.63M | $560.94M |
| 1-day change | -1.71% | -4.63% |
| YTD return | +14.29% | -34.04% |
| 1-year return | +37.05% | -22.26% |
| 5-year return | -72.74% | -40.77% |
| Forward P/E | — | 9.67 |
| EPS (TTM) | $-0.59 | $-0.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.83M | — |
| Revenue growth (YoY) | -58.19% | — |
| Net income (latest FY) | $-64.92M | $-83.50M |
| Gross margin | 73.28% | — |
| Operating margin | -975.91% | — |
| Net margin | -829.58% | — |
| 52-week high | $6.60 | $2.01 |
| 52-week low | $2.46 | $0.84 |
| Distance from 52-week high | -47.88% | -56.68% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +205.23% | +301.98% |
| Average volume | 3.07M | 13.05M |
| Shares outstanding | 158.61M | 644.24M |
| Employees | 69 | 258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed GERN by 59.3 percentage points over the past year.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Geron
GERN stock →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
ACRS vs GERN FAQ
Which is bigger, Aclaris Therapeutics or Geron?
Geron (GERN) is larger, with a market capitalization of $560.94M compared with $545.63M for Aclaris Therapeutics (ACRS).
Which stock has performed better over the past year, ACRS or GERN?
ACRS returned +37.05% over the past 12 months, compared with -22.26% for GERN (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Geron in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.